Alexander K. Arrow

In addition to his role as CFO of Protagenic, Dr. Arrow is the CFO of Carlsmed, Inc., a commercial-stage medical technology company leveraging machine learning technologies and prior outcomes data to personalize the treatment of complex adult spinal deformities. He also serves on the Boards of Zelegent, Inc., which sells a minimally-invasive tool for otolaryngologist sleep specialists to treat snoring, and Paragonix Technologies, which manufactures and sells the leading solid organ transport device. He previously served on the Board of Neumedicines, Inc., an immuno-oncology company developing a first-in-class broad-spectrum anti-cancer agent, and was a Director and the President and Chief Operating Officer of Biolase, Inc. (NASDAQ: BIOL), the world’s lead manufacturer of dental lasers, where he also served as Chair of the Audit and Compensation committees of the Board of Directors. Prior to Biolase, Dr. Arrow was the Chief Medical Officer of Stanford-affiliated neuroscience company Circuit Therapeutics, Inc. Prior to that he spent five years as the Chief Financial Officer of cardiovascular device manufacturer Arstasis, Inc. As CFO of Arstasis, he was part of a team that raised over $100 million in five rounds and launched a first-in-class arterial access technology for interventional cardiologists. Before entering medical technology operating roles, Dr. Arrow spent nine years running medical technology equity research at three Wall Street firms, the last five years as the head of medical technology research at Lazard, Ltd. He also served as the Chief Financial Officer of the Patent & License Exchange, Inc. He began his surgical residency at the UCLA Medical Center in 1996 before leaving to go into business. He has an MD from Harvard Medical School and a BA in Biophysics, magna cum laude, from Cornell University.